The Resveratrol Disappointment: A Decade of Failed Promises

Few supplements have generated as much scientific excitement — and as much scientific disappointment — as resveratrol. Found in small amounts in red wine, grapes, and berries, resveratrol drew enormous research investment after early studies suggested it could activate the sirtuin enzyme SIRT1, extend lifespan in yeast and mice, and partly mimic the effects of calorie restriction. More than two decades later, the supplement has delivered very little of what was originally claimed.

The Promising Start

The story began with Howitz et al. 2003 in Nature (from David Sinclair's lab), showing that resveratrol activated yeast Sir2p and extended yeast replicative lifespan. Baur et al. 2006 in Nature reported that resveratrol improved health and survival in middle-aged mice fed a high-calorie diet. The biotech company Sirtris was founded on this work and was acquired by GlaxoSmithKline for about $720 million in 2008 to develop sirtuin-activating compounds as drugs. Resveratrol supplement sales soared.

Where It Fell Apart

The mechanistic story unravelled when independent labs showed that resveratrol's apparent SIRT1 activation depended on a fluorescent peptide tag used in early in-vitro assays. Pacholec et al. 2010 in the Journal of Biological Chemistry demonstrated that resveratrol does not activate SIRT1 against unmodified peptide substrates; the apparent activation was an assay artefact. In 2010 GSK halted dosing in a multiple-myeloma trial of the resveratrol formulation SRT501 because of renal failure events. By 2013, GSK had folded its Sirtris stand-alone operations into its main R&D structure (some sirtuin-activator programmes continued, but the standalone effort ended). In humans, resveratrol's bioavailability is also poor — it is rapidly metabolised in the gut wall and liver to glucuronide and sulfate conjugates, leaving very low levels of the parent compound in plasma. Pooled RCT data have generally not shown durable improvements in fasting glucose, insulin sensitivity, blood pressure, or body composition, even in patients with type 2 diabetes or cardiovascular risk factors.

What We Learned

Resveratrol's story is a cautionary tale about the distance between animal-model excitement and human efficacy. Yeast, worms, and mice are not small humans. The lesson — that mechanistic elegance in a petri dish or mouse cage is not clinical evidence — is one the supplement and biotech industries continue to relearn with each new molecule.